Sesen Bio Inc.

Sesen Bio, Inc. engages in designing, engineering, and developing targeted protein therapeutics. It offers Vicineum and Proxinium, which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Carisma Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery and development of immunotherapies. It offers chimeric antigen receptor (CAR)-macrophages, a cell therapy platform focusing on the treatment of solid tumors. The company was founded by Michael Klichinsky and Saar Gill in April 2016 and is headquartered in Philadelphia, PA.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--August 5, 2020 – Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced it will be featured as a presenting company at the Canaccord Genuity 40th Annual Growth Conference on Thursday, August 13, 2020.

Sesen Bio to Present Regulatory and Business Development Update at the Canaccord Genuity 40th Annual Growth Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, and Qilu Pharmaceutical, a leading vertically integrated pharmaceutical company in China specializing in the manufacturing and marketing of active pharmaceutical ingredients and drug products, today announced that the companies have entered into an exclusive licensing agreement for the manufacture, development and c

Sesen Bio announces an exclusive license agreement with Qilu Pharmaceutical for the development and commercialization of Vicineum™ in Greater China

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that Company management will host a conference call and webcast on Friday, July 31, 2020 at 8:00 a.m.

Sesen Bio to Host Conference Call to Provide OUS Business Update

Sesen Bio, Inc. (SESN) CEO Dr.

Sesen Bio's (SESN) CEO Thomas Cannell on Q4 2019 Results - Earnings Call Transcript

Sesen Bio: Growing A Position Through The Rolling BLA Summary

Sesen Bio With High Probability FDA Approval Upcoming

Sesen Bio's (SESN) CEO Thomas Cannell on Q3 2019 Results - Earnings Call Transcript

ENZN trades at all time highs, adjusted for dividends, and double the "base case" of the liquidation value.

Bullish On Enzon And Sesen From Different Perspectives

The company reported a positive data update from the Phase 3 VISTA trial for BCG refractory high-grade NMIBC patients.

Sesen Bio: One Step Closer To FDA Approval - An Update

Sesen plunged 35% after announcing a stock offering.

Sesen Bio: Upside From Potential Vicinium Approval

The stock more than doubled within the past two months.

Sesen Bio: What Investors Can Expect Going Forward

Sesen Bio (SESN) needs investors to pay close attention to the stock based on moves in the options market lately.

Options Traders Expect Huge Moves in Sesen Bio (SESN) Stock

The company meets with the FDA on May 20 to discuss manufacturing aspects.

Sesen Bio Looks Better Than Ever - An Update

Sesen Bio, Inc. (SESN) CEO Thomas Cannell on Q1 2019 Results - Earnings Call Transcript

An upcoming data readout for the phase 3 VISTA trial using Vicinium in NMIBC patients who don't respond to BCG therapy is expected by May 13, 2019.

Sesen Bio's Upcoming Data Readout Could Change Things For The Biotech

On March 4, Sesen Bio's President and CEO Dr. Thomas Cannell held a conference call, primarily to update the status and progress of Vicinium.

News for Sesen Bio Inc. Stock (SESN)